Process Research & Development , Merck & Co., Inc. , 126 East Lincoln Avenue , Rahway , New Jersey 07065 , United States.
Process Research & Development , Merck & Co., Inc. , 770 Sumneytown Pike , West Point , Pennsylvania 19486 , United States.
J Org Chem. 2019 Jun 21;84(12):8006-8018. doi: 10.1021/acs.joc.9b00569. Epub 2019 Jun 5.
A practical and efficient enantioselective synthesis of the calcitonin gene-related peptide receptor antagonist 1 has been developed. The key structural component of the active pharmaceutical ingredient is a syn-1,2-amino-fluoropiperidine 4. Two approaches were developed to synthesize this important pharmacophore. Initially, Ru-catalyzed asymmetric hydrogenation of fluoride-substituted enamide 8 enabled the synthesis of sufficient quantities of compound 1 to support early preclinical studies. Subsequently, a novel, cost-effective route to this intermediate was developed utilizing a dynamic kinetic asymmetric transamination of ketone 9. This synthesis also features a robust Ullmann coupling to install a bis-aryl ether using a soluble Cu(I) catalyst. Finally, an enzymatic desymmetrization of meso-diester 7 was exploited for the construction of the γ-lactam moiety in 1.
已开发出一种实用且高效的降钙素基因相关肽受体拮抗剂 1 的对映选择性合成方法。该活性药物成分的关键结构部分是一个 syn-1,2-氨基-氟代哌啶 4。开发了两种方法来合成这种重要的药效团。最初,氟取代烯酰胺 8 的 Ru 催化不对称氢化使合成了足够数量的化合物 1,以支持早期的临床前研究。随后,开发了一种新颖的、具有成本效益的方法,通过酮 9 的动态动力学不对称转氨反应来合成该中间体。该合成还具有使用可溶性 Cu(I)催化剂进行的坚固的 Ullmann 偶联,以安装双芳基醚。最后,利用酶促拆分 meso-二酯 7 来构建 1 中的 γ-内酰胺部分。